Tenet Healthcare Corporation (THC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed results. Basic financial performance is stable, but no year-over-year growth in key metrics. Product development is positive with high-acuity service growth. Market strategy is stable, with successful M&A but no groundbreaking changes. Expenses are managed well, but concerns about payer denials and Medicaid trends persist. Shareholder returns are positive with share repurchases. Q&A insights reveal stable but unimproved payer dynamics and some strategic successes, balancing out the lack of strong guidance changes. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Key Financial Performance
Net Operating Revenues $5.4 billion in Q1 2026, no year-over-year change mentioned.
Consolidated Adjusted EBITDA $1.16 billion in Q1 2026, representing an adjusted EBITDA margin of 21.6%. No specific year-over-year change mentioned.
USPI Adjusted EBITDA $484 million in Q1 2026, a 6% growth over Q1 2025. Growth attributed to disciplined operations and increased distribution of cases.
USPI Same-Facility Revenues Grew 5.3% in Q1 2026, driven by double-digit same-store volume growth in total joint replacements.
Hospital Segment Adjusted EBITDA $678 million in Q1 2026, representing 27.5% of full-year 2026 guidance. EBITDA margin was 16.7%, driven by disciplined expense management and growth initiatives.
Same-Hospital Inpatient Adjusted Admissions Rose 0.6% in Q1 2026, impacted by a 41% decline in respiratory admissions compared to Q1 2025.
Revenue Per Adjusted Admission Declined 1.5% year-over-year in Q1 2026 due to reduced exchange volumes and the absence of $40 million favorable out-of-period supplemental Medicaid revenues from Q1 2025.
Exchange Revenues Represented 6% of consolidated revenues in Q1 2026, a 9% decline from Q1 2025.
Supplemental Medicaid Revenues $304 million in Q1 2026, consistent with guidance and no out-of-period revenues compared to Q1 2025.
Adjusted Free Cash Flow $978 million in Q1 2026, no year-over-year change mentioned.
Cash on Hand $2.97 billion as of March 31, 2026, no year-over-year change mentioned.
Share Repurchase 1.35 million shares repurchased for $318 million in Q1 2026, no year-over-year change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
USPI EBITDA Growth: USPI generated $484 million in adjusted EBITDA, representing 6% growth over the first quarter of 2025. Same-facility revenues grew 5.3%, with double-digit same-store volume growth in total joint replacements in ASCs.
ASC Acquisitions and De Novo Centers: Invested $125 million in the first quarter to acquire 7 ASCs and commenced patient care at 3 de novo centers, achieving half of the targeted full-year spend.
Market Position in Ambulatory Care: The company emphasized its strategic advantage in ambulatory care, supported by investments in USPI and ASC acquisitions.
Operational Efficiencies: Implemented AI-related capabilities in hospitals and physician practices to improve productivity, reduce administrative burden, and enhance patient access. Examples include ambient scribe, automated discharge summaries, and autonomous professional fee coding.
Expense Management: Disciplined expense management contributed to a 21.6% adjusted EBITDA margin. Initiatives included process automation and capacity controls to improve clinical throughput.
Capital Deployment Strategy: Focused on M&A for USPI growth, hospital growth opportunities, share repurchases, and debt management. Repurchased 1.35 million shares for $318 million in Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Payer mix shifts and insurance enrollment uncertainty: The company faces challenges due to shifts in payer mix, seasonal effects, and uncertainties in insurance enrollment in exchanges and Medicaid, which impact demand and financial performance.
Winter storms and vendor cyber attacks: Operations were impacted by two major winter storms and uncertainty from vendor cyber attacks, causing disruptions and requiring rescheduling of procedures.
Decline in exchange coverage: There has been a 10% decline in same-store exchange admissions compared to the previous year, impacting revenue and posing challenges for future exchange volumes.
Reduced exchange volumes and unfavorable payer mix: The company experienced a 9% decline in exchange revenues and unfavorable payer mix, which negatively affected revenue per adjusted admission.
Economic uncertainties and supplemental Medicaid revenues: The company is exposed to uncertainties regarding supplemental Medicaid program revenues, which could impact financial stability if not approved or finalized by CMS.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Adjusted EBITDA Growth: Expected to grow at 10% at the midpoint of the range, excluding non-recurring items and the expiration of premium tax credits.
USPI EBITDA Guidance: USPI's EBITDA for the second quarter is expected to be 24% to 25% of the full year 2026 USPI EBITDA at the midpoint.
Consolidated Adjusted EBITDA Guidance: For the second quarter of 2026, consolidated adjusted EBITDA is expected to be 24% to 25% of the full year consolidated adjusted EBITDA at the midpoint.
Adjusted Free Cash Flow Guidance: Expected to range between $1.6 billion to $1.83 billion for 2026, including $150 million in tax payments for the Conifer transaction. Excluding these tax payments, the midpoint would represent $1.865 billion.
USPI M&A Target: Annual target for USPI M&A is $250 million, with a strong start to the year and future opportunities identified.
Capital Deployment Priorities: Focus on capital investments to grow USPI through M&A, hospital growth opportunities in higher acuity services, share repurchases, and evaluating debt retirement/refinancing opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Tenet Healthcare repurchased 1.35 million shares for $318 million in the first quarter of 2026. The company plans to continue deploying capital for share repurchase over the balance of the year. Management highlighted the significant opportunity to utilize share repurchase at current valuations.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are payer denials increasing in your business, and is the rise in uninsured care related to exchange subsidy expiration?
A:Payer disputes and denials remain high but have not shown a meaningful trend change this quarter compared to last year. The slight increase in uncompensated care may be related to the expiration of exchange subsidies.
Q:What strategies have been successful in the Hospital segment, and are there markets with opportunities for improvement?
A:The hospital business has focused on increasing acuity, transfer centers, new surgical programs, and emergency services. These strategies are implemented across all markets, with some markets showing more impact due to size and state-specific factors like exchange enrollment. Opportunities for efficiency and automation exist in all markets.
Q:Can you elaborate on the length of stay improvements and their impact on high acuity services?
A:Length of stay has decreased by about 3% over the past six quarters, despite a focus on high acuity services. This improvement creates capacity and avoids the need for additional capital investment. New tools and traditional management strategies have contributed to these improvements.
Q:What trends are you seeing in Medicaid and uncompensated care?
A:Medicaid is slightly down, particularly in California, likely due to disenrollment or lack of renewal. There is some hesitation in border communities, but the impact on hospitals has been minimal. Outpatient primary care services in these communities have seen more hesitation.
Q:How are acuity and case mix trends in the hospital and USPI segments?
A:USPI has seen growth in high-acuity services like outpatient joint replacements and robotic surgeries, while low-acuity services have declined. The hospital segment has focused on high-acuity strategies for five years, with temporary impacts from weather and respiratory volume declines this quarter.
Q:What is driving USPI's strong M&A performance, and why is Tenet a preferred acquirer?
A:USPI's success is due to its track record of adding clinical and operational value to acquired assets, efficient operations, and partnerships with health systems. Tenet is a preferred acquirer due to its expertise, robust diligence processes, and ability to execute on high-quality ASC growth.
Q:What was the exchange impact in Q1, and how does it align with full-year guidance?
A:Exchange revenues were about 6% of consolidated revenues in Q1, down from 6.5% last year, representing a 9-10% decrease. This aligns with the full-year guidance of a 20% reduction and $250 million impact.
Q:How did weather and flu impact Q1 performance, and how were costs managed?
A:Respiratory admissions were down 40% in Q1, but month-over-month improvement and early cost flexing helped mitigate the impact. Cost management and efficiency strategies contributed to outperformance in the Hospital segment.
Q:What is the outlook for the outpatient rule and regulatory environment?
A:The company is awaiting the outpatient rule, which may support care in lower-cost settings. Tenet believes it is well-positioned due to its efficient health systems and focus on surgical care at scale.
Q:How should we think about hospital margins for the rest of the year?
A:Hospital margins are expected to grow, supported by expense management initiatives and a return to normal operations. The Q1 margin of 16.7% included some onetime impacts, and full-year guidance implies 15% margins.
Q:What are the trends in payer mix and revenue per adjusted admission?
A:Revenue per adjusted admission was down 1.5% in Q1, primarily due to out-of-period Medicaid adjustments and exchange impacts. Managed care mix remained stable, with strength in Medicare and some commercial coverage pickup.
Q:What is the reserving and revenue recognition approach for exchange patients?
A:The company closely monitors exchange patient coverage and believes it is appropriately reserved. Exchange admissions and revenues were down 9-10% in Q1, aligning with expectations.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific impact of flu and weather disruptions on EBITDA for USPI and hospitals, providing only general comments on cost flexing and operational discipline. Additionally, they did not provide detailed insights into payer mix trends beyond general observations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI capability
ASCs care
ASCs winter
Commission Saum
EMR solution
Medicaid demand
Mr webcast
Officer statement
Saum revenue
Sun detail
USPI digit
USPI start
access program
acuity facility
admission level
advantage market
ambient scribe
analytics workflow
asset USPI
asset mix
attack team
automation length
automation productivity
average environment
balance conclusion
benefit expense
benefit tool
burden access
capacity control
care advantage
care de
case focus
center Hospital
enrollment
headwind
light
party
pilot
shift
THC Transcript
Tenet Healthcare Corporation (THC) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call summary shows mixed results. Basic financial performance is stable, but no year-over-year growth in key metrics. Product development is positive with high-acuity service growth. Market strategy is stable, with successful M&A but no groundbreaking changes. Expenses are managed well, but concerns about payer denials and Medicaid trends persist. Shareholder returns are positive with share repurchases. Q&A insights reveal stable but unimproved payer dynamics and some strategic successes, balancing out the lack of strong guidance changes. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Tenet Healthcare Corporation (THC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Tenet Healthcare Corporation (THC) Q4 2025 Earnings Call Transcript
Positive2-11
The earnings call summary indicates positive sentiment with raised guidance for EBITDA and free cash flow, indicating strong financial performance. The Q&A section revealed management's focus on sustainable expense management and technology adoption, which are positive for long-term growth. While there are concerns about hospital admission growth and Medicaid payments, the overall tone remains optimistic. The company's emphasis on share buybacks and strategic investments further supports a positive outlook. Despite some uncertainties, the raised guidance and strategic initiatives suggest a positive stock price movement in the near term.
Tenet Healthcare Corporation (THC) Q3 2025 Earnings Call Transcript
Positive10-28
The earnings call reflects a positive outlook with raised guidance for EBITDA and revenues, strong free cash flow, and a solid leverage ratio. Share repurchases and strategic capital allocation further enhance shareholder value. Despite some deceleration in USPI growth, management's confidence in handling demand and inflationary pressures suggests stability. The Q&A insights reinforce the company's growth strategies and operational efficiencies, supporting a positive sentiment.
THC Slides
THC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
